National Research Corporation (NRC), listed in the healthcare sector under the health information services industry, stands out with its specialized focus on providing comprehensive analytics and insights aimed at enhancing the patient and employee experience. Based in the United States, NRC holds a market capitalization of $366.94 million, making it a noteworthy player for investors seeking opportunities within niche healthcare services.
Currently priced at $15.91, NRC’s stock has experienced a subtle price change of -0.15 (-0.01%), reflecting relative stability. Over the past year, its trading range has spanned from $10.13 to $22.86, indicating a degree of volatility that could be of interest to risk-tolerant investors.
A significant highlight of NRC’s financial profile is its impressive return on equity (ROE) of 58.28%. This figure suggests exceptional efficiency in generating earnings relative to shareholder equity, a metric that can attract investors looking for high-performance companies. Additionally, NRC boasts a free cash flow of approximately $9.87 million, further underscoring its robust financial health.
Despite the absence of traditional valuation metrics such as P/E ratio, PEG ratio, and price/book value, NRC offers a compelling dividend yield of 3.02%, supported by a payout ratio of 62.34%. This indicates that the company returns a substantial portion of its earnings to shareholders, a feature appealing to income-focused investors.
NRC’s revenue growth has faced challenges, recording a decline of 2.80%. This aspect could raise concerns about the company’s ability to expand its market amid evolving healthcare demands. However, the company’s Earnings Per Share (EPS) of 0.77 reflects underlying profitability, which may be a reassuring factor for potential investors.
Interestingly, NRC lacks current analyst ratings, with no buy, hold, or sell recommendations, and no specified target price range. This absence of coverage could represent an opportunity for investors willing to conduct independent analysis and due diligence to uncover potential value.
On the technical front, NRC’s 50-day and 200-day moving averages are $14.97 and $15.28, respectively, with a Relative Strength Index (RSI) of 29.60, suggesting that the stock might be approaching oversold territory. This could imply potential for price recovery, attracting technical traders looking for entry points.
NRC’s core business model revolves around a portfolio of subscription-based solutions that deliver actionable insights for healthcare organizations. Its offerings span across patient experience, employee engagement, reputation management, and more. Notably, the company’s innovative Huey AI serves as a healthcare experience management companion, showcasing NRC’s commitment to integrating cutting-edge technology into its services.
Founded in 1981 and headquartered in Lincoln, Nebraska, National Research Corporation continues to shape the healthcare analytics landscape. For investors, NRC presents a unique blend of high ROE, attractive dividend yield, and specialized market positioning. While revenue growth challenges and limited analyst coverage pose risks, the company’s strategic focus on enhancing healthcare experiences through advanced analytics positions it well for long-term potential. As always, investors should weigh these factors alongside their investment goals and risk tolerance.
